Among these inhibitors, MCC950 is the best characterized for its potent effect in many diseases with NEK7-NLRP3-mediated inflammasome activation (Wu et al., 2019), including high glucose-induced human retinal endothelial cell dysfunction (diabetic retinopathy) (Zhang Y. et al., 2017), lung ischemia-reperfusion injury (Xu et al., 2018), endometritis in cattle and peritonitis (Kelly et al., 2019). This evidence concerns the gene NEK7 and endometritis.